European Blood Banking Devices Market

The European market for blood banking devices and plasma products is predicted to grow from US$1.7 billion in 2001 to $2.9 billion in 2008, according to a new study from Frost & Sullivan (London, UK, an international marketing consulting company. This is due to the rapid expansion of the plasma products market, increasing use of intravenous immunoglobulin, and the growing adoption of prophylactic treatment for hemophilia.

Overall, there is a growing trend away from blood transfusion toward blood conservation. To offset the effects of dwindling stocks and the risks of rejection and disease associated with blood transfusions, many surgeons are now using noninvasive surgical techniques and making other changes that result in less blood being lost during surgery and less needed for retransfusion.

Rapid developments have been made over the past decade in blood product safety regulations, which are likely to be intensified by the continued research into the risks of blood-borne pathogens. Viral inactivation technologies for blood components will thus fuel the next wave of development.

"The advent of leukoreduction has drastically altered the landscape of the market over the last few years, and pathogen inactivation technology is expected to have an equally profound impact on the make-up of the blood banking arena,” says Frost & Sullivan analyst Tanya Pullen.

The study forecasts that the market will witness a strong movement towards combining device production expertise with biopharmaceutical technology, as companies strive to develop safer blood collection methods and blood substitutes. The automated collection devices sector is expected to display only marginal but steady growth over the forecast period.




Related Links:
Frost & Sullivan